Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.

Mishima K, Sakamoto N, Sekine-Osajima Y, Nakagawa M, Itsui Y, Azuma S, Kakinuma S, Kiyohashi K, Kitazume A, Tsuchiya K, Imamura M, Hiraga N, Chayama K, Wakita T, Watanabe M.

Virology. 2010 Sep 30;405(2):361-9.

Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.

Kurbanov F, Tanaka Y, Matsuura K, Sugauchi F, Elkady A, Khan A, Hasegawa I, Ohno T, Tokuda H, Mizokami M.

J Infect Dis. 2010 Jun 1;201(11):1663-71

Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver.

Kikuchi R, McCown M, Olson P, Tateno C, Morikawa Y, Katoh Y, Bourdet DL, Monshouwer M, Fretland AJ.
Drug Metab Dispos. 2010 Nov;38(11):1954-61.

Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.

Kamiya N, Iwao E, Hiraga N, Tsuge M, Imamura M, Takahashi S, Miyoshi S, Tateno C, Yoshizato K, Chayama K.
J Gen Virol. 2010 Jul;91(Pt 7):1668-77. Epub 2010 Feb 17.

Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry.

Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ.
Gastroenterology. 2009 Aug;137(2):673-81

Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice.

Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, Chayama K, Ohdan H.

J Clin Invest. 2009 Nov;119(11):3226-35.

Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b.

Kurbanov F, Tanaka Y, Chub E, Maruyama I, Azlarova A, Kamitsukasa H, Ohno T, Bonetto S, Moreau I, Fanning LJ, Legrand-Abravanel F, Izopet J, Naoumov N, Shimada T, Netesov S, Mizokami M.
J Infect Dis. 2008 Nov 15;198(10):1448-56.

Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice.

Kimura T, Imamura M, Hiraga N, Hatakeyama T, Miki D, Noguchi C, Mori N, Tsuge M, Takahashi S, Fujimoto Y, Iwao E, Ochi H, Abe H, Maekawa T, Arataki K, Tateno C, Yoshizato K, Wakita T, Okamoto T, Matsuura Y, Chayama K.
J Gen Virol. 2008 Sep;89(Pt 9):2108-13.

Single lymphocyte analysis with a microwell array chip.

Tokimitsu Y, Kishi H, Kondo S, Honda R, Tajiri K, Motoki K, Ozawa T, Kadowaki S, Obata T, Fujiki S, Tateno C, Takaishi H, Chayama K, Yoshizato K, Tamiya E, Sugiyama T, Muraguchi A.
Cytometry A, 2007 Dec;71(12):1003-10.

Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C Virus and its susceptibility to interferon

Hiraga N, Imamura M, Tsuge M, Noguchi C, Takahashi S, Iwao E, Fujimoto Y, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Sakai A, Sakai Y, Honda M, Kaneko S, Wakita T, Chayama K.
FEBS Lett. 2007 May 15;581(10):1983-7. Epub 2007 Apr 20.

Evaluation of Cyclophilin Inhibitor in Hepatitis C Virus-Infected Chimeric Mice In Vivo

Inoue K, Umehara T, Ruegg UT, Yasui F, Watanabe T, Yasuda H, Dumont JM, Scalfaro P, Yoshiba M, Kohara M.
Hepatology. 2007 Apr;45(4):921-8.

Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice

Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M.
Biochem Biophys Res Commun. 2007 Feb 23;353(4):882-8. Epub 2006 Dec 22.

Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model

Umehara T, Sudoh M, Yasui F, Matsuda C, Hayashi Y, Chayama K, Kohara M.

Biochem Biophys Res Commun. 2006 Jul 21;346(1):67-73. Epub 2006 May 24.